Table 1.
Patient demographics and study characteristics.
| Study (year) | Country | Study design | Group | Knees | Male/ Female |
Mean age years (SD) |
Follow-up (month, range) |
DI | SI | Antibiotic type and dose | Modified Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiu et al.5 (2002) | China | RCT | ALBC | 178 | 124/54 | 70 (7.4) | 49 (26–80) | 0 | 2 | Cefuroxime, 2 g | 4 |
| PBC | 162 | 112/50 | 68 (6.9) | 49 (26–80) | 5 | 2 | |||||
| Eveillard et al.14 (2003) | France | RE | ALBC | 83 | 59/108 | – | 12 | 1 | – | Gentamicin, - | 2 |
| PBC | 84 | – | – | 12 | 8 | – | |||||
| Gandhi et al.15 (2009) | Canada | PRO | ALBC | 814 | 285/529 | 65.1 (15.4) | 12 | 18 | 0 | Tobramycin, - | 3 |
| PBC | 811 | 286/543 | 67.2 (10.8) | 12 | 25 | 0 | |||||
| Hinarejos et al.16 (2013) | Spain | RCT | ALBC | 1483 | 346/1137 | 75.8 (7.44) | 12 | 20 | 27 | Erythromycin, 0.5 g | 6 |
| PBC | 1465 | 353/1112 | 76.0 (7.22) | 12 | 20 | 18 | |||||
| Qadir et al.19 (2014) | New Orleans | RE | ALBC | 1486 | 560/926 | 68.13 (10.34) | 1–24 | 20 | – | gentamicin, - tobramycin, - Gentamicin, - |
2 |
| PBC | 1025 | 381/644 | 68.18 (9.84) | 1–24 | 15 | – | |||||
| Gutowski et al.17 (2014) | USA | RE | ALBC | 4826 | 2219/2611 | 65.7 | 24 | 40 | – | Tobramycin, 1 g | 1 |
| PBC | 3048 | 1465/1573 | 65.9 | 24 | 23 | – | |||||
| Hansen et al.18 (2014) | USA | RE | ALBC | 8441 | – | – | >24 | 59 | – | Tobramycin, 1.2 g | 2 |
| PBC | 3053 | – | – | >24 | 61 | – | |||||
| Wang et al.20 (2015) | China | RE | ALBC | 256 | 38/218 | 63.32 (11.13) | – | 1 | – | Gentamicin, 0.5–0.8 g | 2 |
| PBC | 2037 | 351/1686 | 64.97 (10.63) | – | 9 | – | |||||
| Wu et al.21 (2016) | China | RE | ALBC | 2790 | 693/2459 | 69.7 (7.8) | – | 18 | 23 | cefazolin,- vancomycin, - cefuroxime, - gentamycin, - Tobramycin, - |
2 |
| PBC | 362 | – | – | 7 | |||||||
| Sanz-Ruiz et al.22 (2017) | Spain | RE | ALBC | 555 | 183/372 | 77.9 | >24 | – | – | Gentamycin, 0.5 g | 1 |
| PBC | 695 | 250/445 | 76.4 | >24 | – | – | |||||
| Sadullah Turhan3 (2019) | Turkey | RE | ALBC | 85 | 91/415 | 62.8 (10.3) | 1–12 | 1 | 0 | Gentamicin, 1 g | 3 |
| PBC | 421 | – | 1–12 | 6 | 3 |
SD: standard deviation, DI: deep infection, SI: superficial infection, RCT: randomized controlled trail, ALBC: antibiotic-loaded bone cement, PBC: plain bone cement, RE: retrospective trail, PRO: prospective trail.
-: not mentioned.